solid tumours

• 

Circulating tumour DNA as a potential prognostic biomarker for immunotherapy

By Sharon Kell|2020-08-13T08:59:37+00:0013 Aug 2020|Uncategorized|

A study published in Nature Cancer showed that blood levels [...]

Read More

Comments Off on Circulating tumour DNA as a potential prognostic biomarker for immunotherapy

• 

CAR T cell therapy and renal cell carcinoma

By Sharon Kell|2019-11-27T14:50:23+00:0027 Nov 2019|Drug treatments|

In an interview with Targeted Oncology during the 2019 Kidney Cancer [...]

Read More

Comments Off on CAR T cell therapy and renal cell carcinoma

• 

Ilixadencel plus sunitinib combination for metastatic kidney cancer

By Sharon Kell|2019-09-10T15:05:03+00:0010 Sep 2019|Drug treatments|

A combination of ilixadencel plus sunitinib has shown a complete [...]

Read More

Comments Off on Ilixadencel plus sunitinib combination for metastatic kidney cancer

• 

Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours

By Sharon Kell|2018-10-09T13:54:16+00:009 Oct 2018|Drug treatments|

Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing [...]

Read More

Comments Off on Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours

• 

New immuno-oncology treatment to be tested in solid tumours

By Sharon Kell|2017-08-30T15:33:11+00:0030 Aug 2017|Drug treatments|

A new immuno-oncology treatment made by British company, Biotecnol, is about to [...]

Read More

Comments Off on New immuno-oncology treatment to be tested in solid tumours